Metagenomi Therapeutics (MGX) stock price is $0.82, down 1.20% on the day, as of Oct 22, 2026. It has a market cap of $30.98Mn, and is classified in the Gene and Cell Therapy industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap30.98 Mn
P/E-0.33
Add ratio to table…
About
Metagenomi Therapeutics, Inc. is an in vivo genome editing company that was founded on the science of metagenomics to discover and develop curative genetic medicines for patients. The company has generated over 20,000 signature gene editing systems from its proprietary metagenomics database and uses machine learning to refine these tools. Its lead program MGX-001 employs a site specific liver directed gene insertion strategy to deliver durable Factor VIII expression for the…
Metagenomi Therapeutics, Inc. is an in vivo genome editing company that was founded on the science of metagenomics to discover and develop curative genetic medicines for patients. The company has generated over 20,000 signature gene editing systems from its proprietary metagenomics database and uses machine learning to refine these tools. Its lead program MGX-001 employs a site specific liver directed gene insertion strategy to deliver durable Factor VIII expression for the treatment of hemophilia A from a single administration. Beyond hemophilia A, Metagenomi Therapeutics is advancing additional wholly owned candidates that leverage the MGX-001 large gene insertion system for other secreted protein deficiencies such as antithrombin III. The company also pursues partnered programs that focus on protein reduction via gene knockout in cardiometabolic indications through its collaboration with Ionis Pharmaceuticals. All programs aim to achieve curative therapeutics by correcting or modulating disease causing genes using proprietary nucleases and editing platforms. Metagenomi Therapeutics leverages its metagenomics derived nucleases including SMART systems and base editors to expand targeting range and improve precision beyond commonly used CRISPR Cas9 systems.
Metagenomi Therapeutics generates revenue primarily through collaboration agreements licensing fees milestone payments and potential royalties from pharmaceutical partners. In November 2022 the company received an upfront payment of $80 million from Ionis Pharmaceuticals for its Wave 1 drug discovery collaboration covering four cardiometabolic targets. Under the Ionis agreement Metagenomi Therapeutics is eligible to receive up to $29 million in development milestone payments up to $60 million in regulatory milestone payments and up to $250 million in sales based milestones for each licensed product. The company also stands to earn royalties ranging from a mid single digit to a low teens percentage on net sales of any commercialized products arising from the Ionis partnership. As of December 2025 Metagenomi Therapeutics has received $5.8 million in reimbursements for exploratory research expenses under the Ionis agreement with a total potential reimbursement of up to $10 million. In September 2025 the company entered into a non exclusive license with Acuitas Therapeutics for lipid nanoparticle technology requiring an upfront fee of $3 million and obligating Metagenomi Therapeutics to pay maintenance fees milestone payments and low to mid single digit royalties on net sales of products that incorporate the Acuitas LNP platform. Additional revenue may arise from future licensing or partnership arrangements for its proprietary gene editing systems including its SMART nucleases base editors CAST and RIGS technologies.
Metagenomi Therapeutics competes in the genome editing sector alongside companies such as Caribou Biosciences Editas Medicine CRISPR Therapeutics Intellia Therapeutics Sangamo Therapeutics Precision BioSciences Beam Therapeutics Verve Therapeutics Prime Medicine and Tessera Therapeutics. The company’s competitive advantage stems from its proprietary metagenomics derived nucleases which include ultra small SMART systems capable of AAV delivery and a broad repertoire of base editors that achieve high multiplex editing with high specificity. Metagenomi Therapeutics has demonstrated its ability to perform large gene insertion using its CAST technology and to execute programmable RNA and DNA mediated integration via its RIGS platforms. The firm’s intellectual property portfolio comprises 11 issued U S patents 46 pending U S non provisional applications 10 pending U S provisional applications 29 issued foreign patents 295 pending foreign applications and 11 PCT applications covering various nuclease types. This extensive estate provides a barrier to entry and supports long term protection of its therapeutic candidates. Additionally the company’s integration of machine learning with its metagenomics discovery engine enhances the identification of novel editing tools and improves the precision of its gene editing systems.
Metagenomi Therapeutics customer base consists primarily of pharmaceutical and biotechnology partners that collaborate on its drug discovery and development programs. The company’s current collaborators include Ionis Pharmaceuticals with whom it is advancing four cardiometabolic targets in Wave 1 of their partnership and Acuitas Therapeutics which provides lipid nanoparticle technology for its gene editing constructs. These collaborations provide upfront funding research reimbursement milestone payments and potential commercialization pathways for Metagenomi Therapeutics pipeline. While the company has previously worked with entities such as Affini T and Moderna those agreements have been terminated and are not part of its present revenue generating relationships. Ultimately Metagenomi Therapeutics aims to deliver curative therapies to patients suffering from genetic disorders but its near term customers are the partners that fund and support its research and development activities.
Sector:HealthcareSector rationaleMetagenomi Therapeutics is a biotechnology company focused on discovering and developing curative genetic medicines, such as its lead program MGX-001 for hemophilia A. Its revenue model is based on collaboration agreements, licensing fees, and milestone payments from pharmaceutical partners like Ionis Pharmaceuticals for drug discovery and development.Industry:Gene and Cell TherapyGene and Cell TherapyPrimaryMetagenomi Therapeutics is an in vivo genome editing company focusing on curative genetic medicines, utilizing proprietary nucleases and platforms like CAST and RIGS for gene insertion and knockout. Its lead program, MGX-001, specifically employs a gene insertion strategy to treat hemophilia A.Classified using BQ-MICSCIK: 0001785279
Bull & bear
Investment Thesis
▲ Bull case
Metagenomi Therapeutics, Inc. (MGX) is poised to benefit from the growing demand for innovative gene therapy solutions, a sector that has shown consistent growth and is expected to expand at a compound annual growth rate of around 12% through 2030. The company's focus on developing novel therapies for rare genetic disorders positions it well to capture a significant share of this market. MGX's proprietary technology platform enables the precise editing of genes, which could lead to breakthrough treatments for conditions that currently lack effective therapies. The potential for MGX to bring these therapies to market could drive substantial revenue growth and enhance shareholder value.
The company's strategic partnerships and collaborations with leading academic institutions and biotechnology firms provide MGX with access to cutting-edge research and development resources. These collaborations can accelerate the discovery and development of new therapies, reducing the time and cost associated with bringing products to market. The synergies created through these partnerships can also enhance MGX's competitive position in the gene therapy space. The company's ability to leverage these relationships could lead to a pipeline of promising candidates, further bolstering its growth prospects.
MGX's leadership team comprises experienced professionals with a proven track record in the biotechnology and pharmaceutical industries. Their expertise in gene therapy and drug development can guide the company through the complex regulatory landscape and clinical trial processes. The team's strategic vision and operational capabilities are critical for navigating the challenges associated with bringing innovative therapies to market. The company's management is well-positioned to execute its growth strategy and deliver value to shareholders.
The recent investigation by Halper Sadeh LLC into potential breaches of fiduciary duties by certain officers and directors of MGX could be seen as an opportunity for corporate governance reforms. Shareholder involvement in this process can lead to improved transparency, accountability, and oversight mechanisms within the company. These reforms can enhance shareholder value by ensuring that the company operates in the best interests of its investors. The potential for corporate governance improvements could positively impact MGX's stock price and long-term prospects.
Metagenomi Therapeutics, Inc. (MGX) is poised to benefit from the growing demand for innovative gene therapy solutions, a sector that has shown consistent growth and is expected to expand at a compound annual growth rate of around 12% through 2030. The company's focus on developing novel therapies for rare genetic disorders positions it well to capture a significant share of this market. MGX's proprietary technology platform enables the precise editing of genes, which could lead to breakthrough treatments for conditions that currently lack effective therapies. The potential for MGX to bring these therapies to market could drive substantial revenue growth and enhance shareholder value.
The company's strategic partnerships and collaborations with leading academic institutions and biotechnology firms provide MGX with access to cutting-edge research and development resources. These collaborations can accelerate the discovery and development of new therapies, reducing the time and cost associated with bringing products to market. The synergies created through these partnerships can also enhance MGX's competitive position in the gene therapy space. The company's ability to leverage these relationships could lead to a pipeline of promising candidates, further bolstering its growth prospects.
MGX's leadership team comprises experienced professionals with a proven track record in the biotechnology and pharmaceutical industries. Their expertise in gene therapy and drug development can guide the company through the complex regulatory landscape and clinical trial processes. The team's strategic vision and operational capabilities are critical for navigating the challenges associated with bringing innovative therapies to market. The company's management is well-positioned to execute its growth strategy and deliver value to shareholders.
The recent investigation by Halper Sadeh LLC into potential breaches of fiduciary duties by certain officers and directors of MGX could be seen as an opportunity for corporate governance reforms. Shareholder involvement in this process can lead to improved transparency, accountability, and oversight mechanisms within the company. These reforms can enhance shareholder value by ensuring that the company operates in the best interests of its investors. The potential for corporate governance improvements could positively impact MGX's stock price and long-term prospects.
The ongoing investigation by Halper Sadeh LLC into potential breaches of fiduciary duties by certain officers and directors of Metagenomi Therapeutics, Inc. (MGX) raises significant concerns about corporate governance and management integrity. Such investigations can lead to legal and regulatory scrutiny, which may divert management's attention from core business operations. The potential for legal actions and settlements could also result in substantial financial and reputational costs for the company. These risks could negatively impact MGX's stock price and investor confidence.
The gene therapy sector, while promising, is highly competitive and fraught with regulatory and technical challenges. MGX faces intense competition from established players and emerging biotechnology firms, all vying for a share of the market. The high costs and lengthy timelines associated with clinical trials and regulatory approvals can pose significant hurdles for the company. Failure to successfully navigate these challenges could result in delays or setbacks in MGX's product pipeline, impacting its revenue growth and financial performance.
The reliance on strategic partnerships and collaborations introduces dependencies that could pose risks for MGX. Changes in the priorities or financial health of its partners could affect the company's ability to advance its research and development programs. Additionally, intellectual property disputes or disagreements over the direction of collaborative projects could lead to disruptions in MGX's operations. These risks could hinder the company's progress and limit its ability to bring innovative therapies to market.
The regulatory landscape for gene therapies is complex and subject to change, which could impact MGX's ability to obtain approvals for its products. Regulatory bodies may impose stringent requirements or additional clinical trial mandates, which could delay the commercialization of MGX's therapies. The company's financial resources and operational capabilities will be tested as it navigates these regulatory challenges. Failure to meet regulatory standards could result in significant setbacks for MGX, affecting its market position and financial prospects.
The ongoing investigation by Halper Sadeh LLC into potential breaches of fiduciary duties by certain officers and directors of Metagenomi Therapeutics, Inc. (MGX) raises significant concerns about corporate governance and management integrity. Such investigations can lead to legal and regulatory scrutiny, which may divert management's attention from core business operations. The potential for legal actions and settlements could also result in substantial financial and reputational costs for the company. These risks could negatively impact MGX's stock price and investor confidence.
The gene therapy sector, while promising, is highly competitive and fraught with regulatory and technical challenges. MGX faces intense competition from established players and emerging biotechnology firms, all vying for a share of the market. The high costs and lengthy timelines associated with clinical trials and regulatory approvals can pose significant hurdles for the company. Failure to successfully navigate these challenges could result in delays or setbacks in MGX's product pipeline, impacting its revenue growth and financial performance.
The reliance on strategic partnerships and collaborations introduces dependencies that could pose risks for MGX. Changes in the priorities or financial health of its partners could affect the company's ability to advance its research and development programs. Additionally, intellectual property disputes or disagreements over the direction of collaborative projects could lead to disruptions in MGX's operations. These risks could hinder the company's progress and limit its ability to bring innovative therapies to market.
The regulatory landscape for gene therapies is complex and subject to change, which could impact MGX's ability to obtain approvals for its products. Regulatory bodies may impose stringent requirements or additional clinical trial mandates, which could delay the commercialization of MGX's therapies. The company's financial resources and operational capabilities will be tested as it navigates these regulatory challenges. Failure to meet regulatory standards could result in significant setbacks for MGX, affecting its market position and financial prospects.